(P015) Radiation Biological Responses of MRI-Linac vs Linac in Human Head and Neck and Lung Cancer Cells

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

The 1.5-T MF generated by MRL had no effect on the viability or radioresponses of NSCLC or HNSCC cell lines in vitro. These results suggest that MRL, as a novel cancer treatment technology, has the potential not to influence the radiotherapy outcome of patients. Considering the complicated in vivo microenvironment, further in vivo study is warranted.

Li Wang, Marco van Vulpen, Zhifei Wen, Stan Hoogcarspel, David P. Molkentine, Jan Kok, Steven Hsesheng Lin, R. Broekhuizen, Kie-kian Ang, A.N. Bovenschen, Bas Raaymakers, Steven Jay Frank; UT MD Anderson Cancer Center; University of Utrecht Medical Center

OBJECTIVE: The MRI-Linac (MRL) is a novel radiotherapy technology designed to enable high cure rates with low toxicity and treatment response monitoring. However, the biological influence on radioresponses of human solid tumors within the 1.5-T magnetic field (MF) generated by MRL is unknown. Our hypothesis is that the 1.5-T MF has no influence on cell viability or radiation effects.

METHODS: Two non–small-cell lung carcinoma (NSCLC) lines (H460 and H1299) and two head and neck squamous cell carcinoma (HNSCC) lines (HN-5 and UMSCC-47) were used. The influences of a 1.5-T MF on in vitro cell viability and on cellular radioresponses were determined by cell plate efficiency (PE) and by clonogenic cell survival assay (CSA) after exposing the cells to graded single doses or fractionated 6 MV radiation using Linac (100 MU/min) or MRL (134 MU/min), respectively. The experiments were performed with cell flasks placed inside a 37°C water bath with an optimized radiation dose distribution. The radiation output of Linac and the MRL was measured with a corrected chamber. The physical dose received by the cells was verified using radiation detectors. The results were analyzed by t-test.

RESULTS: Our results supported a very strong trend that MF, as a single factor, had no influence on cell viability. No significant PE change occurred after single exposure or multiple exposures to MF compared with the Linac environment for the four cell lines (12 of 16 experiments; all P > .05) except for one experiment with the H460 cells (borderline; P = .044) andthree experiments withUMSCC-47 cells. Similarly, single exposure or multiple exposures to MF had no influence on cell radioresponse (all P > .05). When the cells were exposed to MRL or Linac treatment for up to four times, no significant changes were observed for the D0s for with MF vs without MF (all P > .05).

CONCLUSIONS: The 1.5-T MF generated by MRL had no effect on the viability or radioresponses of NSCLC or HNSCC cell lines in vitro. These results suggest that MRL, as a novel cancer treatment technology, has the potential not to influence the radiotherapy outcome of patients. Considering the complicated in vivo microenvironment, further in vivo study is warranted.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Recent Videos
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Although accuracy remains a focus in whole-body MRI testing in patients with Li-Fraumeni syndrome, comfortable testing experiences may ease anxiety.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.
Funding a clinical trial to further assess liquid biopsy in patients with Li-Fraumeni syndrome may help with detecting cancers early across the board.
Related Content